Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

BACKGROUND: Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (PiRD) diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Welzel, Tatjana, Winskill, Carolyn, Zhang, Nancy, Woerner, Andreas, Pfister, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995584/
https://www.ncbi.nlm.nih.gov/pubmed/33766063
http://dx.doi.org/10.1186/s12969-021-00514-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995584/
https://www.ncbi.nlm.nih.gov/pubmed/33766063
http://dx.doi.org/10.1186/s12969-021-00514-4

Ejemplares similares